The recurrence rate of patients with Graves' disease (GD) is estimated to be 50-55% after withdrawal of antithyroid drug therapy, and relapse is frequent in the first year after discontinuing the medication. Follow-up examination of these patients frequently reveals laboratory findings consistent with subclinical thyrotoxicosis in the first year after stopping the antithyroid agents. We investigated the risk of recurrence of GD among patients with resurfacing subclinical thyrotoxicosis state after remission of initial GD with antithyroid treatments. Materials and Methods: We reviewed the patients diagnosed with GD who visited the Department of Endocrinology at two tertiary medical centers: Wonju Severance Christian Hospital and Gangneung Asan Hospital. We enrolled patients whose GD was completely treated after initial treatment with antithyroid agents who then developed subclinical thyrotoxicosis after discontinuation of antithyroid agents. Results: We reviewed a total of 44 patients (29 females, 15 males; age, 48.93±18.04; range, 17-85 years). The recurrence rate was 27.3% (12/44 patients), and recurrence occurred 3 months to 12 months later resurfacing of subclinical thyrotoxicosis. Patients with recurred GD was significantly older than non-recurred patients (44.63±17.75 years vs. 58.58±15.48 years, p=0.02). Other clinical parameters measured at the time of initial diagnosis were not different between the two groups. Conclusion: The recurrence rate of GD in patients with resurfacing subclinical thyrotoxicosis after initial remission of the disease was less than 30%. A close monitoring is recommended in these subgroup patients, especially in older patients.
Introduction
The most common cause of hyperthyroidism is known to be Graves' disease (GD). Antithyroid drug therapy is primarily used as first-line therapy for GD in many Asian countries, including Korea. 1, 2) If patients with GD experience adverse effects of antithyroid agents or if remission is not achieved despite pro-longed antithyroid drug therapy, thyroidectomy or radioactive iodine therapy can also be considered.
When ingested, antithyroid drug immediately enters the thyroid gland and inhibits the oxidation and organizing of iodine involved in thyroid hormone production process while also inhibiting the formation of thyroxine (T4) and triiodothyronine (T3) by interfering with the coupling of iodotyrosines. 3) Recently, it has also been known that antithyroid drug has anti-inflammatory and 
Materials and Methods
We reviewed the patients diagnosed with GD who was considered to be significant. The recurrence of GD occurred at 3 months to 12 months after resurfacing of subclinical thyrotoxicosis. Table 1 shows the clinical data, level of free T4, TSH, and TSI at initial diagnosis of GD and at subclinical thyrotoxicosis state. The level of TSI at time of initial di- TSI levels and the age or sex did not show significant associations with recurrence. 7) In another studies showed average age at diagnosis was significantly younger at non-remission group compared with remission group after antithyroid drug therapy for GD. 8, 9) But, our data showed opposite result. We guess the reasons of this differences may be due to the differences of compliance or amount of iodide intake. But we could not prove this results, so, further evaluation about age factor for recurrence of GD in patients with subclinical thyrotoxicosis state after antithyroid drug therapy withdrawal is needed.
Results
TSI values at initial diagnosis were not significantly different between remission and recurrence group. It is generally known that higher TSI level at the time of diagnosis of GD is associated with higher likelihood of GD recurrence. 10, 11) Although most studies suggest the decision to discontinue antithyroid agents should be made based on TSI level, 1, 2) there is no significant difference in TSI level between patients who developed GD recurrence and those who remained disease-free in our study. We guess the reason of no differences of initial TSI level between patients with recurrence and remission in our study is because we did not investigate all patients treated with antithyroid agents for GD but only those who temporarily developed subclinical thyrotoxicosis state. However, TSI level at the time of GD diagnosis were high in patients with relapsed GD, although statistically not significant, which suggests its value in predicting the recurrence at least indirectly.
TSI levels were significantly lowered at the time of subclinical thyrotoxicosis state after drug withdrawal than at the time of diagnosis of GD. This may have been because the decision to complete treatment with antithyroid agents was made based on TSI levels.
We suggest that patients with older age at the time of diagnosis of GD are more likely to develop recurrence, and therefore, this subset of patients requires closer monitoring following completion of antithyroid drug therapy.
This study was a retrospective study performed through a chart survey, and there was a limit to the degree in which the data could be analyzed. Another limitation of this study is that the data were collected across two hospitals uses different testing machines and reagents for measuring free T4, T3, and TSI.
However, the normal range was not significantly different and the unit of laboratory data was same, so the data were combined. This study is a small-scale, simple-design retrospective study. However, no study has reported the rate of GD recurrence among patients who develops subclinical thyrotoxicosis following antithyroid drug therapy for GD, at least in Korea, and this data may serve as a base for future large-scale prospective study.
In summary, close laboratory monitoring rather than resumption of antithyroid drug therapy is recommended in patients with resurfacing subclinical thyrotoxicosis after initial remission of GD achieved with antithyroid drug therapy because the actual GD recurrence rate is low in such population.
